









Markets
/
Stocks
/
nasdaq-ntra
/

Natera Inc

NTRA

203.040USD

+5.960+3.02%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

27.92BMarket Cap

LossP/E TTM



Natera Inc

203.040

+5.960+3.02%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Natera Inc

Currency: USD Updated: 2026-02-06

Key Insights

Natera Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 14 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 255.88.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Natera Inc's Score

Industry at a Glance

Industry Ranking

14 / 75

Overall Ranking

83 / 4521

Industry

Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Natera Inc Highlights

StrengthsRisks

Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 106.88% year-on-year.

Fairly Valued

The company’s latest PE is -88.79, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 128.15M shares, decreasing 3.11% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 1.84K shares of this stock.

Analyst Rating

Based on 22 analysts

Buy

Current Rating

255.879

Target Price

+29.84%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Natera Inc is 8.19, ranking 32 out of 75 in the Healthcare Providers & Services industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 592.18M, representing a year-over-year increase of 34.66%, while its net profit experienced a year-over-year increase of 177.11%.

Score

Industry at a Glance

Previous score

8.19

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.09

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.79

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.70

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.36

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Natera Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Natera Inc is 7.33, ranking 32 out of 75 in the Healthcare Providers & Services industry. Its current P/E ratio is -88.79, which is -92.60% below the recent high of -6.57 and -32.21% above the recent low of -117.39.

Score

Industry at a Glance

Previous score

7.33

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 14/75

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Natera Inc is 8.55, ranking 8 out of 75 in the Healthcare Providers & Services industry. The average price target is 239.00, with a high of 280.00 and a low of 186.00.

Score

Industry at a Glance

Previous score

8.55

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 22 analysts

Buy

Current Rating

255.879

Target Price

+29.84%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Natera Inc

NTRA

CVS Health Corp

CVS

Teladoc Health Inc

TDOC

HCA Healthcare Inc

HCA

Tenet Healthcare Corp

THC

Universal Health Services Inc

UHS

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Natera Inc is 6.97, ranking 35 out of 75 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 237.35 and the support level at 181.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.73

Change

0.24

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-9.491

Sell

RSI(14)

29.897

Sell

STOCH(KDJ)(9,3,3)

12.304

Oversold

ATR(14)

9.520

High Vlolatility

CCI(14)

-180.214

Sell

Williams %R

83.887

Oversold

TRIX(12,20)

-0.257

Sell

StochRSI(14)

31.498

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

212.902

Sell

MA10

224.479

Sell

MA20

231.267

Sell

MA50

233.637

Sell

MA100

210.620

Sell

MA200

184.076

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Natera Inc is 10.00, ranking 1 out of 75 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 92.10%, representing a quarter-over-quarter decrease of 1.96%. The largest institutional shareholder is The Vanguard, holding a total of 12.25M shares, representing 8.80% of shares outstanding, with 2.61% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

12.33M

-2.30%

T. Rowe Price Associates, Inc.

Star Investors

11.82M

-2.05%

JP Morgan Asset Management

9.68M

+8.56%

BlackRock Institutional Trust Company, N.A.

6.79M

+0.15%

Farallon Capital Management, L.L.C.

4.25M

-11.79%

State Street Investment Management (US)

3.39M

+2.17%

Duquesne Family Office LLC

Star Investors

3.21M

+4.19%

Geode Capital Management, L.L.C.

2.60M

+1.73%

Franklin Advisers, Inc.

2.58M

+33.29%

Wellington Management Company, LLP

2.56M

-2.95%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Natera Inc is 8.37, ranking 12 out of 75 in the Healthcare Providers & Services industry. The company's beta value is 1.65. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Natera Inc’s latest ESG disclosure leads the Healthcare Providers & Services industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.